Genetic data is revolutionizing precision medicine and creating new opportunities for clinical trials. These trials often fail when investigators lack understanding of the role of genetic data in precision medicine. This session explores how genetics has impacted clinical trials, and what improvements as well as barriers it creates for protocol design, patient recruitment and execution.
The panel discusses the challenges in the design of a trial that includes genetics, why companies are using genetics in their trials, and the value of genetics in the new era of precision medicine.
- Ken Getz – Director of Sponsored Programs, Center for the Study of Drug Development, Tufts University School of Medicine
- Karmen Trzupek – Director, Ocular & Rare Disease Genetics Services, InformedDNA
- Jill Johnston – President, Site Activation, WCG Clinical Services
- Travis Quigley – Senior Director, Clinical Development, bluebird bio